|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma显示文摘AIM:To examine the significance of branched-chain amino acid (BCAA) treatment before transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).METHODS:This study included 99 patients who underwent TACE therapy for HCC at our hospital and were followed up without treatment for at least 6 mo between January 2004 and January 2010.They were divided into 2 groups:those receiving BCAA granules (n=40) or regular diet (n=59,control).Data obtained were retrospectively analyzed (prior to TACE,and 1 wk,1,3,and 6 mo after TACE) in terms of nutritional condition and clinical laboratory parameters (serum albumin level and Child-Pugh score),both of which are determinants of hepatic functional reserve.RESULTS:The BCAA group comprised 27 males and 13 females with a mean age of 69.9 ± 8.8 years.The patients of the BCAA group were classified as follows:Child-Pugh A/B/C in 22/15/3 patients,and Stage Ⅱ/Ⅲ /ⅣA HCC in 12/23/5 patients,respectively.The controlgroup comprised 32 males and 27 females with a mean age of 73.2 ± 10.1 years.In the control group,9 patients had chronic hepatitis,Child-Pugh A/B/C in 39/10/1 patients,and StageⅠ/Ⅱ/Ⅲ/ⅣA HCC in 1/11/35/12 patients,respectively.Overall,both serum albumin level and Child-Pugh score improved significantly in the BCAA group as compared with the control 3 and 6 mo after TACE (P < 0.05).Further analysis was performed by the following categorization:(1) child-Pugh classification;(2) liver cirrhosis subgroup with a serum albumin level > 3.5 g/dL;and (3) epirubicin dose.A similar trend indicating a significant improvement of all variables in the BCAA group was noted (P < 0.05).CONCLUSION:Treatment with BCAA granules in patients who have undergone TACE for HCC is considered useful to maintain their hepatic functional reserve. | Hiroki Nishikawa Yukio Osaki Tadashi Inuzuka Haruhiko Takeda Jun Nakajima Fumihiro Matsuda Shinichiro Henmi Azusa Sakamoto Tetsuro Ishikawa Sumio Saito Ryuichi Kita Toru Kimura | 2012 | World Journal of Gastroenterology2012，18，12： | 16 |
| 2 | Generation and replication-dependent dilution of 5fC and 5caC during mouse preimplantation development显示文摘epigenetic 领域里的最近的进展之一是蛋白质的 Tet 家庭能够催化 DNA 的 5-methylcytosine (5mC ) 的变换到 5-hydroxymethylcytosine (5hmC ) 的示范。有趣地,最近的研究证明了 5hmC 能被 Tet 蛋白质进一步氧化产生 5-formylcytosine (5fC ) 和 5-carboxylcytosine (5caC ) ,它能被胸腺嘧啶 DNA glycosylase (TDG ) 移开。决定到 5fC 和 5caC 的 5mC 的催化 Tet 的变换是否在接合子发生在 vivo,我们产生了为 5fC 和 5caC 特定的抗体。由 immunostaining,我们证明在父亲的前核的 5mC 的损失与 5fC 和 5caC 的外观是并发的,类似于 5hmC 的。而不是快速通过催化酶的进程被移开,重要地, 5fC 和 5caC 在鼠标 preimplantation 开发期间展出复制依赖者冲淡。这些结果不仅在接合子表明 5mC 的变换到 5fC 和 5caC,而且显示 5fC 和 5caC 是相对稳定的并且可能在 preimplantation 开发期间功能。和以前的研究,我们的学习建议到 5hmC/5fC/5caC 的 5mC 的那催化 Tet 的变换在 preimplantation 开发期间为父亲的 DNA demethylation 由复制依赖者冲淡报道列在后面。 | Azusa Inoue Li Shen Qing Dai Chuan He Yi Zhang | 2011 | Cell Research2011，21，12： | 11 |
| 3 | Dynamics of 5-methylcytosine and 5-hydroxymethylcytosine during germ cell reprogramming显示文摘以前的研究揭示了初发的细菌房间(PGC ) 经历的那只老鼠为 totipotency 重设 epigenome 的染色体宽的 DNA methylation reprogramming。然而,有 5-hydroxymethylcytosine (5hmC ) 的产生的精确 5-methylcytosine (5mC ) 动力学和它的关系不是清楚的。这里,我们在 PGC reprograming 和细菌房间开发期间分析了 5mC 和 5hmC 的动力学。出人意料地,我们在 5mC 和 5hmC 层次在哪个期间是低的期间发现了一个特定的时期(E8.5-9.5 ) 。随后, 5hmC 层次增加在 E11.5 到达它的山峰并且逐渐地由复制依赖者冲淡多半减少直到 E13.5。有趣地, 5hmC 在这个时期期间在 chromocenters 被充实。当时这个细菌房间特定的 5hmC subnuclear 本地化模式甚至在成熟卵母细胞在女细菌房间被维持,当有丝分裂的增长在新生的阶段期间恢复,如此的模式逐渐地在男细菌房间被失去。Pericentric 5hmC 在 silencing 起一个重要作用主要卫星重复,特别在女 PGC。由 RNA-seq 的全球 transcriptome 分析表明差别的大多数从 E9.5 表示了基因到 13.5 是在男、女的 PGC 的 upregulated。尽管仅仅女 PGC 在出生前的阶段期间进入成熟分裂,成熟分裂相关并且印的基因的一个子集是显著地在在 E13.5 的男、女的 PGC 的 upregulated。因此,我们的学习不仅在 PGC reprogramming 和细菌房间期间揭示 5mC 和 5hmC 的动力学开发,而且他们在 epigenetic reprogramming 和 meiotic 和印的基因的 transcriptional 规定的潜在的角色。 | Shinpei Yamaguchi Kwonho Hong Rui Liu Azusa Inoue Li Shen Kun Zhang Yi Zhang | 2013 | Cell Research2013，23，3： | 10 |
| 4 | Promising biological therapies for ulcerative colitis: A review of the literature显示文摘Ulcerative colitis(UC) is a chronic lifelong condition characterized by alternating flare-ups and remission. There is no single known unifying cause, and the pathogenesis is multifactorial, with genetics, environmental factors, microbiota, and the immune system all playing roles. Current treatment modalities for UC include 5-aminosalicylates, corticosteroids, immunosuppressants(including purine antimetabolites, cyclosporine, and tacrolimus), and surgery. Therapeutic goals for UC are evolving. Medical treatment aims to induce remission and prevent relapse of disease activity. Infliximab, an anti-tumor necrosis factor(TNF)-α monoclonal antibody, is the first biological agent for the treatment of UC. Over the last decade, infliximab and adalimumab(anti-TNF-α agents) have been used for moderate to severe UC, and have been shown to be effective in inducing and maintaining remission. Recent studies have indicated that golimumab(another anti-TNF-α agent), tofacitinib(a Janus kinase inhibitor), and vedolizumab and etrolizumab(integrin antagonists), achieved good clinical remission and response rates in UC. Recently, golimumab and vedolizumab have been approved for UC by the United States Food and Drug Administration. Vedolizumab may be used as a first-line alternative to anti-TNF-α therapy in patients with an inadequate response to corticosteroids and/or immunosuppressants. Here, we provide updated information on various biological agents in the treatment of UC. | Hirotada Akiho Azusa Yokoyama Shuichi Abe Yuichi Nakazono Masatoshi Murakami Yoshihiro Otsuka Kyoko Fukawa Mitsuru Esaki Yusuke Niina Haruei Ogino | 2015 | World Journal of Gastrointestinal Pathophysiology2015，6，4： | 8 |
| 5 | Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity显示文摘 | F. Ann Ran Patrick D. Hsu Chie-Yu Lin Jonathan S. Gootenberg Silvana Konermann Alexandro E. Trevino David A. Scott Azusa Inoue Shogo Matoba Yi Zhang Feng Zhang | 2013 | Cell2013，，2： | 4 |
| 6 | A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients显示文摘 | Noriko Satoh-Asahara Yousuke Sasaki Hiromichi Wada Mayu Tochiya Azusa Iguchi Reiko Nakagawachi Shinji Odori Shigeo Kono Koji Hasegawa Akira Shimatsu | 2012 | Metabolism2012，，： | 3 |
| 7 | Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study显示文摘 | Yukio Osaki Yoshihide Ueda Hiroyuki Marusawa Jun Nakajima Toru Kimura Ryuichi Kita Hiroki Nishikawa Sumio Saito Shinichiro Henmi Azusa Sakamoto Yuji Eso Tsutomu Chiba | 2012 | Journal of Gastroenterology2012，，4： | 3 |
| 8 | Transcriptional activation of transposable elements in mouse zygotes is independent of Tet3-mediated 5-methylcytosine oxidation显示文摘父亲的染色体的 methylation 状态是很快立即在授精以后的 reprogrammed。最近的研究在接合子揭示了 5-methylcytosine (5mC ) 的那损失有 5-hydroxymethylcytosine (5hmC ) 的外观的相互关联, 5-formylcytosine (5fC ) ,和 5-carboxylcytosine (5caC ) 。这个过程被 Tet3 和在接合子产生的 5mC 氧化产品调停逐渐地通过一个复制依赖者冲淡过程在 preimplantation 开发期间被失去。尽管有这些调查结果,到在接合子的 5hmC/5fC/5caC 的 5mC 的调停 Tet3 的氧化的生物意义是未知的。DNA methylation 包括 transposable 元素(TE ) 的压抑在 silencing 基因表示起一个重要作用。给 TE 的激活与 DNA methylation 的损失在 preimplantation 开发期间相关,父亲的 DNA demethylation 可以在 TE 激活有一个重要角色,这被相信。这里,我们检验了这个假设并且发现调停 Tet3 的 5mC 氧化没有重要贡献到 TE 激活。我们证明 LINE-1 (长散布的核苷酸元素 1 ) 和 ERVL (内长的 retroviruses 班 III ) 的表示在接合子从父亲、母亲的染色体被激活。由 Tet3 的调停 siRNA 的弄空的 5mC 氧化的抑制在接合子影响了既不 TE 激活,也不全球抄写。因此,我们的学习提供证明在接合子的 TE 和全球抄写的激活独立于调停 Tet3 的 5mC 氧化的第一条证据。 | Azusa Inoue | 2012 | Cell Research2012，22，12： | 2 |
| 9 | Separation of WAP-8294A components,a novel anti-methicillin-resistant Staphylococcus aureus antibiotic,using high-speed counter-current chromatography显示文摘 | Kenichi H Masanao S Azusa K | 2001 | J Chromatogr A2001，932，1： | 1 |
| 10 | Acceleration and stabilization techniques for the Levenberg-Marquardt method 显示文摘 | Hiroyasu S Katsuya M Azusa K | 2005 | Communications and Computer Sciences2005，88，7： | 1 |
| 11 | Treatment of central sleep apnea in patients with heart failure: Now and future显示文摘Heart failure (HF) is known to be associated with sleep-disordered breathing(SDB). In addition to disturbing patients’ sleep, SDB is also associated with a deterioration in the cardiac function and an increased mortality and morbidity.Central sleep apnea (CSA), typically characterized by Cheyne-Stokes breathing(CSB), is increasingly found in patients with HF compared to the general population. An important pathogenetic factor of CSA seen in HF patients is an instability in the control of the respiratory system, characterized by both hypocapnia and increased chemosensitivity. Sympathetic overactivation,pulmonary congestion and increased chemosensitivity associated with HF stimulate the pulmonary vagal irritant receptor, resulting in chronic hyperventilation and hypocapnia. Additionally, the repetitive apnea and arousal cycles induce cyclic sympathetic activation, which may worsen the cardiac prognosis. Correcting CSB may improve both patient’s quality of life and HF syndrome itself. However, a treatment for HF in patients also experiencing CSA is yet to be found. In fact, conflicting results from numerous clinical studies investigating sleep apnea with HF guide to a troubling question, that is whether(or not) sleep apnea should be treated in patients with HF? This editorial attempts to both collect the current evidence about randomized control trials investigating CSA in patients with HF and highlight the effect of specific CSA treatments on cardiovascular endpoints. | Azusa Murata Takatoshi Kasai | 2019 | World Journal of Respirology2019，9，1： | 1 |
| 12 | Contribution of the net charge to the regulatory effects of amino acids and epsilon–poly(L–lysine)on the gelatinization behavior of potato starch granules显示文摘 | Azusa I Makoto H Tadashi Y | 2006 | Bioscience Biotechnology and Biochemistry2006，70，16： | 1 |
| 13 | Ambulatory blood pressure, blood pressure variability and the prevalence of carotid artery alteration: the Ohasama study 显示文摘 | Yoriko Shintania Masahiro Kikuyaa Azusa Haraa | 2007 | J Hypertens2007，25，： | 1 |
| 14 | Prognosis for Pedunculated hepatocellular carcinoma显示文摘 | Yutaka H Azusa S Hisao T | | 0，，1： | 1 |
| 15 | Acceleration atelectasis in aviators of air raft with OBOGS(T4)显示文摘 | AZUSA K HIROKAZU M KEISAKU S | 1994 | The reports of aeromedical laboratory1994，35，4： | 1 |
| 16 | Increase in the expression of an alpha-amylase gene and sugar accumulation induced during cold period reflects shoot elongation in hyacinth bulbs 显示文摘 | AZUSA S HIROSHI O KAZUYUKI S | 2006 | Journal of the American Society for Horticulture Science2006，131，2： | 1 |
| 17 | Or- ganocatalytic a-Hydroxymethylation of Cyelopen- tanone with Aqueous Formaldehyde: Easy Access to Chiral &Lactones显示文摘 | NOBUYUKI M AZUSA I MASAKI N | 2009 | Bioorganic b- medicinal Chem- istry Letters2009，19，14： | 1 |
| 18 | Hepatic pseudolymphoma: imaging–pathologic correlation with special reference to hemodynamic analysis显示文摘 | Kotaro Yoshida Satoshi Kobayashi Osamu Matsui Toshifumi Gabata Junichiro Sanada Wataru Koda Tetsuya Minami Yasuji Ryu Kazuto Kozaka Azusa Kitao | 2013 | Abdominal Imaging2013，，6： | 1 |
| 19 | Changes in digoxin pharmacokinetics treated with lipopolysacchafide in Wistar rats显示文摘 | Ryuji K Azusa F Takako K Jun M Machiko N Yuri T | 2008 | Biol Pharm Bull2008，31，6： | 1 |
| 20 | Endothelial to Mesenchymal Transition via Transforming Growth Factor-β1/Smad Activation Is Associated with Portal Venous Stenosis in Idiopathic Portal Hypertension显示文摘 | Azusa Kitao Yasunori Sato Seiko Sawada-Kitamura Kenichi Harada Motoko Sasaki Hiroyasu Morikawa Susumu Shiomi Masao Honda Osamu Matsui Yasuni Nakanuma | 2009 | The American Journal of Pathology2009，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员